Overcome Barriers to Psychedelic Therapies for CNS DiseasesSeminar · Bob Dagher, MD · Clinilabs · Clinical PharmacologyMon, Dec 14, 2026 · 17:00 UTC
The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris HeifetsFrom Our Neurons to Yours